Pleased to meet you, we are Galapagos, a dynamic growing Biotech company with offices across Europe and in the US, headquartered in Mechelen, Belgium.
We’re in the business of changing lives. In our quest to discover and develop life-improving medicines we go where no one has ever gone before. In every challenge we face, we see new opportunities. We pioneer for patients. We need thought leaders and rapid thinkers, entrepreneurs in spirit and status quo-fighters. Collaborative innovators and perseverant idealists. We need the best-in-class. In other words, we need you: The ‘make-it-happener’.
We are looking for an Associate Director Mass Spectrometry (Mechelen, BE)
Scope of the job
You are part of a team that develops biochemical, biophysical and cellular assays to support our internal small molecule (SM) and biologics drug discovery programs.
You lead a team of Mass Spectrometry specialists covering a broad range of activities, including measuring SM and protein analytes as well as the interaction between SM and proteins using state-of-the-art equipment such as Sciex triple Quad, RapidFire, qTOF or Fusion Orbitrap. This comprises managing the team but also supporting hands-on in experimental design, assay development, optimizing the methodology per target, generating high quality data, analysing and communicating the data in a structured manner as a key member of discovery projects.
The Associate Director Mass Spectrometry is also responsible for developing the MS platform in collaboration with external companies, identifying novel binding sites in proteins via covalent approaches, support the hit identification, characterization, and optimization. You de-risk covalent drug candidates with different techniques including cell-based selectivity assays using full proteomic analysis.
Your coordination and strategic planning for our dedicated analytical team, is an enabler for continued development of our Mass Spectrometry platform, advancing Galapagos' discovery portfolio using unique insights into mode of action of our drug candidates.
